Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)

Mazen Noureddin¹, Emily Truong², Rebeca Mayo³, Ibon Martínez-Arranz³, Itziar Mincholé³, Jesus M Banales^{4

5}, Marco Arrese⁶, Kenneth Cusi⁷, María Teresa Arias-Loste⁸, Radan Bruha⁹, Manuel Romero-Gómez¹⁰, Paula Iruzubieta⁸, Rocio Aller¹¹, Javier Ampuero¹², José Luis Calleja¹³, Luis Ibañez-Samaniego¹⁴, Patricia Aspichueta^{15

16

17}, Antonio Marín-Duce¹⁸, Tatyana Kushner¹⁹, Pablo Ortiz³, Stephen A Harrison²⁰, Quentin M Anstee²¹, Javier Crespo⁸, José M Mato^{17

22}, Arun J Sanyal²³

Affiliations

¹ Department of Hepatology, Houston Liver Institute, Houston Research Institute, Houston, Texas, USA.
² Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
³ OWL Metabolomics, Derio, Spain.
⁴ Biodonostia Research Institute, Donostia University Hospital, University of the Basque Country (UPV-EHU), CIBERehd, IKERBASQUE, Donostia, Spain.
⁵ Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
⁶ Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
⁷ Department of Medicine, University of Florida, Gainesville, Florida, USA.
⁸ Department of Gastroenterology and Hepatology Marqués de Valdecilla University Hospital, Cantabria University, IDIVAL, Santander, Spain.
⁹ Fourth Department of Internal Medicine, General University Hospital and the First Faculty of Medicine, Charles University, Prague, Czech Republic.
¹⁰ Digestive Diseases Unit and CIBERehd, Valme University Hospital, CIBERehd, Seville, Spain.
¹¹ Clinic University Hospital, University of Valladolid, Valladolid, Spain.
¹² UCM Digestive Diseases, Virgen del Rocío University Hospital, Sevilla, Spain.
¹³ Department of Gastroenterology and Hepatology, Puerta del Hierro University Hospital, Madrid, Spain.
¹⁴ Liver Unit, Gregorio Marañón University Hospital, Madrid, Spain.
¹⁵ Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain.
¹⁶ Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
¹⁷ National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Madrid, Spain.
¹⁸ Príncipe de Asturias University Hospital, Alcalá University, Madrid, Spain.
¹⁹ Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
²⁰ Pinnacle Clinical Research, San Antonio, Texas, USA.
²¹ Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
²² CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Derio, Spain.
²³ Virginia Commonwealth University Medical Center, Richmond, Virginia, USA.

PMID: 39325967
DOI: 10.1097/HEP.0000000000001061

Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)

Mazen Noureddin et al. Hepatology. 2025.

. 2025 Jan 1;81(1):E12-E16.

doi: 10.1097/HEP.0000000000001061. Epub 2024 Sep 26.

Authors

Affiliations

¹ Department of Hepatology, Houston Liver Institute, Houston Research Institute, Houston, Texas, USA.
² Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
³ OWL Metabolomics, Derio, Spain.
⁴ Biodonostia Research Institute, Donostia University Hospital, University of the Basque Country (UPV-EHU), CIBERehd, IKERBASQUE, Donostia, Spain.
⁵ Department of Biochemistry and Genetics, School of Sciences, University of Navarra, Pamplona, Spain.
⁶ Department of Gastroenterology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
⁷ Department of Medicine, University of Florida, Gainesville, Florida, USA.
⁸ Department of Gastroenterology and Hepatology Marqués de Valdecilla University Hospital, Cantabria University, IDIVAL, Santander, Spain.
⁹ Fourth Department of Internal Medicine, General University Hospital and the First Faculty of Medicine, Charles University, Prague, Czech Republic.
¹⁰ Digestive Diseases Unit and CIBERehd, Valme University Hospital, CIBERehd, Seville, Spain.
¹¹ Clinic University Hospital, University of Valladolid, Valladolid, Spain.
¹² UCM Digestive Diseases, Virgen del Rocío University Hospital, Sevilla, Spain.
¹³ Department of Gastroenterology and Hepatology, Puerta del Hierro University Hospital, Madrid, Spain.
¹⁴ Liver Unit, Gregorio Marañón University Hospital, Madrid, Spain.
¹⁵ Department of Physiology, Faculty of Medicine and Nursing, University of the Basque Country UPV/EHU, Leioa, Spain.
¹⁶ Biocruces Bizkaia Health Research Institute, Barakaldo, Spain.
¹⁷ National Institute for the Study of Liver and Gastrointestinal Diseases (CIBERehd, Instituto de Salud Carlos III), Madrid, Spain.
¹⁸ Príncipe de Asturias University Hospital, Alcalá University, Madrid, Spain.
¹⁹ Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
²⁰ Pinnacle Clinical Research, San Antonio, Texas, USA.
²¹ Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.
²² CIC bioGUNE, Basque Research and Technology Alliance (BRTA), Derio, Spain.
²³ Virginia Commonwealth University Medical Center, Richmond, Virginia, USA.

PMID: 39325967
DOI: 10.1097/HEP.0000000000001061

No abstract available

PubMed Disclaimer

References

1. Noreddin M, Truong E, Mayo R, Martínez-Arranz I, Mincholé I, Banales J, et al. Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF). Hepatology. 2024;79:135–148.
1. Martíinez-Arranz I, Mayo R, Pérez-Cormenzana M, Mincholé I, Salazar L, Alonso C, et al. Enhancing metabolomics research through data mining. J Proteomics. 2015;127:275–288.

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Wolters Kluwer

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)

Affiliations

Letter to the Editor: Serum identification of at-risk MASH: The metabolomics-advanced steatohepatitis fibrosis score (MASEF)

Authors

Affiliations

References

LinkOut - more resources

Full Text Sources